
Mitochondria-targeted tetrapeptide
Elamipretide (SS-31)
Mitochondria-targeted tetrapeptide. Supplied for laboratory research use only.
- Mitochondria-targeted tetrapeptide; FDA-approved (accelerated) as Forzinity
- Approval limited to Barth syndrome patients 30kg and up
- Not approved by EMA, MHRA, or TGA
- Supplied for laboratory research use only. Not for human or veterinary use.
90-Day Money-Back Guarantee
Every order is covered for ninety days from delivery. If you decide against it inside that window, contact us and we will refund the purchase price.
Research use only. Not for human or veterinary use or consumption. This product is not approved by the FDA and is not intended to diagnose, treat, cure or prevent any disease.
What it is
Development status
Elamipretide is approved by the FDA as a prescription medicine. Forzinity received accelerated approval on 19 September 2025 to improve muscle strength in Barth syndrome patients weighing at least 30kg. That is a rare-disease approval, not a general mitochondrial, anti-ageing or performance approval. This product is not that medicine and is supplied for laboratory research use only.
Development status is stated above. No efficacy claim is made on this page.
Shipping & returns
The specifics
The details, if you want them.
Development
Where it is up to.
Peer-reviewed and the basis for FDA accelerated approval for one narrow rare-disease indication. Not approved by the EMA, MHRA, or TGA.
Questions
The questions people actually ask.
What is elamipretide?
Is this the same as Forzinity?
What does "Research Use Only" mean?
How is this vial supplied?
What is your refund policy?